Arno Therapeutics has reported the positive results from a Phase II clinical study of AR-67, used for treating patients with glioblastoma multiforme.

The open-label and multicentre trial enrolled 16 patients and showed the efficacy of the brain cancer drug.

Northwestern University Neurology assistant professor Jeffrey Raizer said the results of the interim analysis are encouraging enough to warrant further clinical testing.

AR-67 is a camptothecin analogue that acts by inhibiting topoisomerase I activity.